OneSource Specialty Pharma has received an Establishment Information Report (EIR) with a 'Voluntary Action Indicated' (VAI) status from the U.S. Food and Drug Administration (USFDA) for its BLD facility in Bangalore. The report follows an inspection of the facility, conducted from November 14 - 22, 2024.
OneSource operates five state-of-the-art cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies.
OneSource Specialty Pharma formerly known as Stelis Biopharma, is India’s first specialty pharma pure-play CDMO business.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: